Trials & Filings
Related Searches:
Filter by:
166 - 180 of 604 results
January 21, 2010
Merck’s HIV treatment vicriviroc did not meet the primary efficacy endpoint in two Phase III studies involving patients previously treated with other HIV medicines.
Read More »
January 18, 2010
The FDA has extended the review period for OSI Pharmaceuticals and Genentech’s sNDA for Tarceva (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
Read More »
January 13, 2010
Xcellerex, Inc. has initiated a Phase I trial of XRX-001, a prophylactic vaccine against yellow fever, a tropical virus disease that is often fatal.
Read More »
January 6, 2010
Gilead’s Phase II trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of GS 9350, elvitegravir and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1, met its pr
Read More »
January 4, 2010
The FDA has not yet completed its review of the BLA for Prevnar 13, Pfizer’s13-valent pneumococcal conjugate vaccine.
Read More »
December 30, 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) received a Complete Response letter from the FDA for ceftobiprole.
Read More »
December 30, 2009
Valeant Pharmaceuticals’ NDA for the investigational drug retigabine has been accepted for review by the FDA.
Read More »
December 30, 2009
Pfizer has shut down the Phase III trial of figitumumab (CP-751,871)
Read More »
December 28, 2009
Pfizer received a Complete Response letter from the FDA regarding its NDA for Lyrica (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD).
Read More »
December 28, 2009
Synta Pharmaceuticals Corp. has initiated a Phase II trial of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).
Read More »
December 15, 2009
Darusentan missed its primary endpoints, will likely be canceled.
Read More »
December 8, 2009
Mylan to sell generic Effexor XR in mid-2011
Read More »
December 7, 2009
Roche will discontinue development of Genmab's RG1507, an IFG-1R antibody.
Read More »
December 4, 2009
AZ's Seroquel XR gets adjunctive MDD indication, but also response letter for other sNDAs
Read More »
December 2, 2009
Alexion Pharmaceuticals’s RI facility is near approval as a second source of supply for Soliris.
Read More »
166 - 180 of 604 results
